BACKGROUND & AIMS:
:The present study aimed to assess switch from immediate-release (IR) to extended-release (XR) quetiapine in terms of efficacy, tolerability, compliance, and quality of life in a sample of patients with mood disorders. Thirty patients, 10 with major depressive disorder and 20 with bipolar disorder, with residual depressive symptoms, who had switched from quetiapine IR (mean 365 mg/day) to XR (mean 373 mg/day), were recruited and evaluated using different psychometric scales, administered at T0 (switch), T1, and T2 (1 and 6 weeks after the switch, respectively). A significant reduction from T0 to T2 of the total scores on the Hamilton depression rating scale (t=2.15; P=0.04), Hamilton anxiety scale (t=3.04; P=0.006), and clinical global impression-severity item (t=2.8; P=0.01) was found. No differences were found in terms of compliance and quality of life. The switch was well tolerated by 2/3 of patients. Most reported side effects were early/central insomnia with day drowsiness (16.7%), increased appetite and weight (8.4%), mild asthenia (4.2%), and constipation (4.2%), which, in two cases, led to switch interruption. Strategies to relieve side effects, including gradual cross-switch, improved switch feasibility. Switch from quetiapine IR to XR seems to be associated with clinical improvement in major depressives with residual symptoms, although some patients may report side effects because of the different pharmacokinetics.
背景与目标:
:本研究旨在评估情绪障碍患者样本中喹硫平从速释(IR)到缓释(XR)的转变。从不同的心理测验量表中招募并评估了30例患者,其中10例重度抑郁症和20例双相情感障碍并伴有抑郁症残留症状,他们从喹硫平IR(平均365 mg /天)转为XR(平均373 mg /天),并进行了评估。 ,分别在T0(切换),T1和T2(分别在切换后1周和6周)进行管理。汉密尔顿抑郁量表(t = 2.15; P = 0.04),汉密尔顿焦虑量表(t = 3.04; P = 0.006)和临床总体印象严重度项目(t = 2.8; P = 0.01)。在依从性和生活质量方面没有发现差异。 2/3的患者对开关的耐受性良好。报告的副作用最多的是早期/中枢失眠,伴有嗜睡(16.7%),食欲和体重增加(8.4%),轻度乏力(4.2%)和便秘(4.2%),其中两例导致开关中断。缓解副作用的策略(包括逐步交叉切换)提高了切换的可行性。从喹硫平IR转为XR似乎与具有残留症状的主要抑郁症的临床改善有关,尽管一些患者可能因药代动力学不同而报告副作用。